Dr Mwebesa said the ministry of health in DRC has confirmed the outbreak of EVD in Magina Health Zone of Mabalako in North Kivu about 100 kilometres from Uganda's border.
The experimental vaccine, which is manufactured by Merck, proved successful during its first wide-scale usage against an outbreak in north-western Congo that was declared over less than two weeks ago.More news: Google Pixel 3 XL just leaked in an unboxing video
The North Kivu Provincial Health Division notified the government of Congo that a couple of cases of haemorrhagic fevers were reported.
The World Health Organization has said it hopes to know as early as Tuesday whether the Ebola strain in this new outbreak is the one for which the vaccine can be used.
Congo has 3,000 doses of the vaccine in stock and health workers there have been busy setting up a so-called cold chain to keep them well below freezing, a major challenge in Congo's tropical climate. Of the three healthcare workers who were affected, one has died.More news: Meghan Markle’s Birthday Gifts: What She Can and Can’t Keep
This region north of North Kivu province is already threatened by armed groups including the fearsome Ugandan Allied Democratic Forces (ADF) who have terrorized Beni for several years.
Testing by the Institut National de Recherche Biomédicale has suggested that the virus causing this outbreak belongs to the Ebola Zaire species.
Heavily traveled borders nearby with Uganda and Rwanda also complicate efforts to contain the disease, which is spread via contact with the bodily fluids of those infected, including the dead. More than one million displaced people are now residing in the affected region, which shares borders with Rwanda and Uganda. It will be even harder to reach the target population this time, because this outbreak took place in a region where active civil conflicts have displaced over 1 million civilians.More news: Tesla board confirms Elon Musk's buyout plans